This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
2022 International Bladder Cancer Network
Viewing 1-20 of 42 articles
IBCN 2022: Epigenomic Mapping Identifies a Super-Enhancer Repertoire That Regulates Bladder Cancer Cell Identity Through Distinct Transcription Factor Networks
IBCN 2022: Automated, Cell-Based Measurements Can Define Low-Grade and High-Grade Noninvasive Papillary Urothelial Carcinoma and Predict Time to Recurrence
IBCN 2022: Validation of a GATA2 Methylation and FGFR3 Mutation Assay To Predict Progression in BCG-Treated High-Risk Non-Muscle-Invasive Bladder Cancer
IBCN 2022: Proteomic Profiling of Muscle Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy
IBCN 2022: Novel Clinic-Genomic Score Predicting Outcomes With Platinum-Based Chemotherapy in Patients With Treatment Naïve, Metastatic Urothelial Cancer
IBCN 2022: IBCN Biobank Consortium - Overcoming Barriers in Data Sharing
IBCN 2022: Genome-Wide Circulating Tumor DNA for Monitoring Treatment Response and Metastatic Relapse in Bladder Cancer
IBCN 2022: Clinical Application of CG0070 in Bladder Cancer: Lessons Learned
IBCN 2022: ICAM-1 Targeted Immunotherapeutic Coxsackievirus A21 (CVA21) as an Oncolytic Agent for Non-Muscle Invasive Bladder Cancer
IBCN 2022: Oncolytic Virotherapy
IBCN 2022: General Data Protection Regulation (GDPR) and Data Sharing
IBCN 2022: The Cancer Genome Atlas (TCGA) – Lessons Learned
IBCN 2022: The UROMOL Project, Molecular Characteristics of NMIBC to Identify and Validate Biomarkers of Recurrence and Progression
IBCN 2022: Targeting HLA-E and NKG2A for the Treatment of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
IBCN 2022: Spatial Prioritization of Cellular Interactions in the Tumor Microenvironment
IBCN 2022: ATM Loss and Therapeutic Vulnerabilities in Bladder Cancer
IBCN 2022: NPEPPS Can Be Targeted To Overcome Cisplatin Resistance in Patient-Derived Bladder Cancer Tumoroids
IBCN 2022: Immunotherapy of Bladder Cancer Through STING Activation Empowered by Urease-Nanomotor Nanoparticle System
IBCN 2022: Tumor Cell-Intrinsic Expression of FGFR3 Drives Anti-PD-1 Immunotherapy Resistance in a Murine Bladder Cancer Model
IBCN 2022: The Accuracy of Cystoscopy in Predicting Detrusor Invasion in Newly Diagnosed Bladder Cancer Patients
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free